Obesity drug supply delay not unusual says Novo Nordisk CEO


4 August 2022 - Novo Nordisk sought to soothe concerns about supplies of its new obesity drug Wegovy (semagutide) on Thursday, saying there was nothing unusual about a slight delay in its availability.

"We see that across our own facilities also from time to time," Jorgensen added.

Read Reuters article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Supply